#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Nonalcoholic fatty liver disease ( NAFLD ) represents the leading cause of progressive liver disorders worldwide , affecting between 20 % to 40 % of the adult population .
3-1	17-29	Nonalcoholic	abstract[4]	new[4]	coref	6-47[0_4]
3-2	30-35	fatty	abstract[4]	new[4]	_	_
3-3	36-41	liver	object|abstract[4]	new|new[4]	coref	3-14
3-4	42-49	disease	abstract[4]	new[4]	_	_
3-5	50-51	(	_	_	_	_
3-6	52-57	NAFLD	organization	new	coref	4-1
3-7	58-59	)	_	_	_	_
3-8	60-70	represents	_	_	_	_
3-9	71-74	the	abstract[6]	new[6]	_	_
3-10	75-82	leading	abstract[6]	new[6]	_	_
3-11	83-88	cause	abstract[6]	new[6]	_	_
3-12	89-91	of	abstract[6]	new[6]	_	_
3-13	92-103	progressive	abstract[6]|abstract[8]	new[6]|new[8]	_	_
3-14	104-109	liver	abstract[6]|object|abstract[8]	new[6]|giv|new[8]	coref	4-22
3-15	110-119	disorders	abstract[6]|abstract[8]	new[6]|new[8]	_	_
3-16	120-129	worldwide	abstract[6]|abstract[8]	new[6]|new[8]	_	_
3-17	130-131	,	_	_	_	_
3-18	132-141	affecting	_	_	_	_
3-19	142-149	between	_	_	_	_
3-20	150-152	20	quantity[9]	new[9]	coref	4-30[22_9]
3-21	153-154	%	quantity[9]	new[9]	_	_
3-22	155-157	to	_	_	_	_
3-23	158-160	40	quantity[10]	new[10]	_	_
3-24	161-162	%	quantity[10]	new[10]	_	_
3-25	163-165	of	quantity[10]	new[10]	_	_
3-26	166-169	the	quantity[10]|person[11]	new[10]|new[11]	_	_
3-27	170-175	adult	quantity[10]|person[11]	new[10]|new[11]	_	_
3-28	176-186	population	quantity[10]|person[11]	new[10]|new[11]	_	_
3-29	187-188	.	_	_	_	_

#Text=NAFLD is defined by increased hepatic fat accumulation not explained by alcohol abuse , and it encompasses a wide spectrum of liver injuries , ranging from simple steatosis ( >5 % of liver weight ) to its inflammatory form nonalcoholic steatohepatitis ( NASH ) .
4-1	189-194	NAFLD	organization	giv	coref	6-1
4-2	195-197	is	_	_	_	_
4-3	198-205	defined	_	_	_	_
4-4	206-208	by	_	_	_	_
4-5	209-218	increased	abstract[15]	new[15]	_	_
4-6	219-226	hepatic	abstract|abstract[15]	new|new[15]	coref	13-33
4-7	227-230	fat	substance|abstract[15]	new|new[15]	_	_
4-8	231-243	accumulation	abstract[15]	new[15]	_	_
4-9	244-247	not	_	_	_	_
4-10	248-257	explained	_	_	_	_
4-11	258-260	by	_	_	_	_
4-12	261-268	alcohol	abstract[16]	new[16]	ana	4-16[0_16]
4-13	269-274	abuse	abstract[16]	new[16]	_	_
4-14	275-276	,	_	_	_	_
4-15	277-280	and	_	_	_	_
4-16	281-283	it	abstract	giv	ana	4-37
4-17	284-295	encompasses	_	_	_	_
4-18	296-297	a	abstract[18]	new[18]	_	_
4-19	298-302	wide	abstract[18]	new[18]	_	_
4-20	303-311	spectrum	abstract[18]	new[18]	_	_
4-21	312-314	of	abstract[18]	new[18]	_	_
4-22	315-320	liver	abstract[18]|object|event[20]	new[18]|giv|new[20]	coref|coref|coref|coref	4-33|14-31[143_20]|4-33|14-31[143_20]
4-23	321-329	injuries	abstract[18]|event[20]	new[18]|new[20]	_	_
4-24	330-331	,	_	_	_	_
4-25	332-339	ranging	_	_	_	_
4-26	340-344	from	_	_	_	_
4-27	345-351	simple	abstract[21]	new[21]	coref	14-16[0_21]
4-28	352-361	steatosis	abstract[21]	new[21]	_	_
4-29	362-363	(	_	_	_	_
4-30	364-366	>5	quantity[22]	giv[22]	_	_
4-31	367-368	%	quantity[22]	giv[22]	_	_
4-32	369-371	of	quantity[22]	giv[22]	_	_
4-33	372-377	liver	quantity[22]|object|abstract[24]	giv[22]|giv|new[24]	coref|coref	9-8|9-8
4-34	378-384	weight	quantity[22]|abstract[24]	giv[22]|new[24]	_	_
4-35	385-386	)	_	_	_	_
4-36	387-389	to	_	_	_	_
4-37	390-393	its	abstract|abstract[27]	giv|new[27]	appos|appos	4-43[0_27]|4-43[0_27]
4-38	394-406	inflammatory	abstract[27]	new[27]	_	_
4-39	407-411	form	abstract|abstract[27]	new|new[27]	_	_
4-40	412-424	nonalcoholic	abstract[27]	new[27]	_	_
4-41	425-440	steatohepatitis	abstract[27]	new[27]	_	_
4-42	441-442	(	_	_	_	_
4-43	443-447	NASH	abstract	giv	coref	5-1
4-44	448-449	)	_	_	_	_
4-45	450-451	.	_	_	_	_

#Text=NASH may be complicated by the presence of fibrosis and , eventually , it may progress to cirrhosis and hepatocellular carcinoma ( HCC ) .
5-1	452-456	NASH	substance	giv	coref	6-52
5-2	457-460	may	_	_	_	_
5-3	461-463	be	_	_	_	_
5-4	464-475	complicated	_	_	_	_
5-5	476-478	by	_	_	_	_
5-6	479-482	the	abstract[30]	new[30]	coref	21-26[209_30]
5-7	483-491	presence	abstract[30]	new[30]	_	_
5-8	492-494	of	abstract[30]	new[30]	_	_
5-9	495-503	fibrosis	abstract[30]|abstract	new[30]|new	ana	5-14
5-10	504-507	and	_	_	_	_
5-11	508-509	,	_	_	_	_
5-12	510-520	eventually	_	_	_	_
5-13	521-522	,	_	_	_	_
5-14	523-525	it	abstract	giv	coref	6-54
5-15	526-529	may	_	_	_	_
5-16	530-538	progress	_	_	_	_
5-17	539-541	to	_	_	_	_
5-18	542-551	cirrhosis	abstract	new	_	_
5-19	552-555	and	_	_	_	_
5-20	556-570	hepatocellular	abstract|abstract[35]	new|new[35]	appos|appos	5-23[0_35]|5-23[0_35]
5-21	571-580	carcinoma	abstract[35]	new[35]	_	_
5-22	581-582	(	_	_	_	_
5-23	583-586	HCC	abstract	giv	_	_
5-24	587-588	)	_	_	_	_
5-25	589-590	.	_	_	_	_

#Text=NAFLD has a strong inherited component , and variants in proteins regulating hepatocellular lipid handling , including patatin-like phospholipase domain-containing 3 ( PNPLA3 ) , transmembrane 6 superfamily member 2 ( TM6SF2 ) , membrane bound O-acyltransferase domain-containing 7 ( MBOAT7 ) , predispose to the disease development and progression to NASH and fibrosis .
6-1	591-596	NAFLD	abstract	giv	coref	7-20
6-2	597-600	has	_	_	_	_
6-3	601-602	a	abstract[38]	new[38]	_	_
6-4	603-609	strong	abstract[38]	new[38]	_	_
6-5	610-619	inherited	abstract[38]	new[38]	_	_
6-6	620-629	component	abstract[38]	new[38]	_	_
6-7	630-631	,	_	_	_	_
6-8	632-635	and	_	_	_	_
6-9	636-644	variants	object[39]	new[39]	coref	10-18[88_39]
6-10	645-647	in	object[39]	new[39]	_	_
6-11	648-656	proteins	object[39]|substance	new[39]|new	coref	11-23
6-12	657-667	regulating	_	_	_	_
6-13	668-682	hepatocellular	abstract[42]	new[42]	_	_
6-14	683-688	lipid	object|abstract[42]	new|new[42]	coref	23-18
6-15	689-697	handling	abstract[42]	new[42]	_	_
6-16	698-699	,	abstract[42]	new[42]	_	_
6-17	700-709	including	abstract[42]	new[42]	_	_
6-18	710-722	patatin-like	abstract[42]|event[44]	new[42]|new[44]	_	_
6-19	723-736	phospholipase	abstract[42]|abstract|event[44]	new[42]|new|new[44]	_	_
6-20	737-754	domain-containing	abstract[42]|event[44]	new[42]|new[44]	_	_
6-21	755-756	3	abstract[42]|event[44]	new[42]|new[44]	_	_
6-22	757-758	(	_	_	_	_
6-23	759-765	PNPLA3	abstract	new	_	_
6-24	766-767	)	_	_	_	_
6-25	768-769	,	_	_	_	_
6-26	770-783	transmembrane	abstract[47]	new[47]	_	_
6-27	784-785	6	person[46]|abstract[47]	new[46]|new[47]	_	_
6-28	786-797	superfamily	person[46]|abstract[47]	new[46]|new[47]	_	_
6-29	798-804	member	abstract[47]	new[47]	_	_
6-30	805-806	2	abstract[47]	new[47]	_	_
6-31	807-808	(	_	_	_	_
6-32	809-815	TM6SF2	person	new	_	_
6-33	816-817	)	_	_	_	_
6-34	818-819	,	_	_	_	_
6-35	820-828	membrane	object[49]	new[49]	_	_
6-36	829-834	bound	object[49]	new[49]	_	_
6-37	835-852	O-acyltransferase	event[50]	new[50]	_	_
6-38	853-870	domain-containing	event[50]	new[50]	_	_
6-39	871-872	7	event[50]	new[50]	_	_
6-40	873-874	(	event[50]	new[50]	_	_
6-41	875-881	MBOAT7	event[50]	new[50]	_	_
6-42	882-883	)	event[50]	new[50]	_	_
6-43	884-885	,	_	_	_	_
6-44	886-896	predispose	_	_	_	_
6-45	897-899	to	_	_	_	_
6-46	900-903	the	abstract[52]	new[52]	coref	7-20[67_52]
6-47	904-911	disease	abstract|abstract[52]	giv|new[52]	coref	15-34
6-48	912-923	development	abstract[52]	new[52]	_	_
6-49	924-927	and	_	_	_	_
6-50	928-939	progression	event[53]	new[53]	coref	14-19[138_53]
6-51	940-942	to	event[53]	new[53]	_	_
6-52	943-947	NASH	event[53]|abstract|abstract[55]	new[53]|giv|new[55]	coref|coref|coref|coref	10-15|10-15[87_55]|10-15|10-15[87_55]
6-53	948-951	and	event[53]|abstract[55]	new[53]|new[55]	_	_
6-54	952-960	fibrosis	event[53]|abstract[55]|abstract	new[53]|new[55]|giv	coref	9-8[79_0]
6-55	961-962	.	_	_	_	_

#Text=Dietary habits such as excessive caloric intake , fructose consumption , and physical inactivity represent other risk factors for NAFLD development .
7-1	963-970	Dietary	abstract|object[58]	new|new[58]	_	_
7-2	971-977	habits	object[58]	new[58]	_	_
7-3	978-982	such	object[58]	new[58]	_	_
7-4	983-985	as	object[58]	new[58]	_	_
7-5	986-995	excessive	object[58]|abstract[60]	new[58]|new[60]	_	_
7-6	996-1003	caloric	object[58]|abstract|abstract[60]	new[58]|new|new[60]	_	_
7-7	1004-1010	intake	object[58]|abstract[60]	new[58]|new[60]	_	_
7-8	1011-1012	,	object[58]	new[58]	_	_
7-9	1013-1021	fructose	object[58]|abstract|abstract[62]	new[58]|new|new[62]	_	_
7-10	1022-1033	consumption	object[58]|abstract[62]	new[58]|new[62]	_	_
7-11	1034-1035	,	object[58]	new[58]	_	_
7-12	1036-1039	and	object[58]	new[58]	_	_
7-13	1040-1048	physical	object[58]|abstract[63]	new[58]|new[63]	_	_
7-14	1049-1059	inactivity	object[58]|abstract[63]	new[58]|new[63]	_	_
7-15	1060-1069	represent	_	_	_	_
7-16	1070-1075	other	abstract[65]	new[65]	coref	14-8[133_65]
7-17	1076-1080	risk	abstract|abstract[65]	new|new[65]	_	_
7-18	1081-1088	factors	abstract[65]	new[65]	_	_
7-19	1089-1092	for	abstract[65]	new[65]	_	_
7-20	1093-1098	NAFLD	abstract[65]|organization|abstract[67]	new[65]|giv|giv[67]	ana|coref|ana|coref	8-4[0_67]|9-15|8-4[0_67]|9-15
7-21	1099-1110	development	abstract[65]|abstract[67]	new[65]|giv[67]	_	_
7-22	1111-1112	.	_	_	_	_

#Text=In addition , its pathogenesis is closely intertwined with excessive adiposity , insulin resistance ( IR ) , and metabolic syndrome .
8-1	1113-1115	In	_	_	_	_
8-2	1116-1124	addition	_	_	_	_
8-3	1125-1126	,	_	_	_	_
8-4	1127-1130	its	abstract|abstract[69]	giv|new[69]	coref|coref|coref|coref	10-29[93_0]|12-5[108_69]|10-29[93_0]|12-5[108_69]
8-5	1131-1143	pathogenesis	abstract[69]	new[69]	_	_
8-6	1144-1146	is	_	_	_	_
8-7	1147-1154	closely	_	_	_	_
8-8	1155-1166	intertwined	_	_	_	_
8-9	1167-1171	with	_	_	_	_
8-10	1172-1181	excessive	abstract[70]	new[70]	_	_
8-11	1182-1191	adiposity	abstract[70]	new[70]	_	_
8-12	1192-1193	,	_	_	_	_
8-13	1194-1201	insulin	event|abstract[72]	new|new[72]	appos|coref|appos|coref	8-16[0_72]|10-22|8-16[0_72]|10-22
8-14	1202-1212	resistance	abstract[72]	new[72]	_	_
8-15	1213-1214	(	_	_	_	_
8-16	1215-1217	IR	abstract	giv	coref	9-1
8-17	1218-1219	)	_	_	_	_
8-18	1220-1221	,	_	_	_	_
8-19	1222-1225	and	_	_	_	_
8-20	1226-1235	metabolic	person|abstract[75]	new|new[75]	_	_
8-21	1236-1244	syndrome	abstract[75]	new[75]	_	_
8-22	1245-1246	.	_	_	_	_

#Text=IR even correlates with the severity of liver fibrosis , the main determinant of NAFLD prognosis .
9-1	1247-1249	IR	abstract	giv	coref	11-4
9-2	1250-1254	even	_	_	_	_
9-3	1255-1265	correlates	_	_	_	_
9-4	1266-1270	with	_	_	_	_
9-5	1271-1274	the	abstract[77]	new[77]	_	_
9-6	1275-1283	severity	abstract[77]	new[77]	_	_
9-7	1284-1286	of	abstract[77]	new[77]	_	_
9-8	1287-1292	liver	abstract[77]|object|abstract[79]	new[77]|giv|giv[79]	appos|coref|appos|coref	9-11[80_79]|15-20|9-11[80_79]|15-20
9-9	1293-1301	fibrosis	abstract[77]|abstract[79]	new[77]|giv[79]	_	_
9-10	1302-1303	,	_	_	_	_
9-11	1304-1307	the	abstract[80]	giv[80]	coref	10-3[0_80]
9-12	1308-1312	main	abstract[80]	giv[80]	_	_
9-13	1313-1324	determinant	abstract[80]	giv[80]	_	_
9-14	1325-1327	of	abstract[80]	giv[80]	_	_
9-15	1328-1333	NAFLD	abstract[80]|abstract|abstract[82]	giv[80]|giv|new[82]	coref|coref	10-11|10-11
9-16	1334-1343	prognosis	abstract[80]|abstract[82]	giv[80]|new[82]	_	_
9-17	1344-1345	.	_	_	_	_

#Text=Indeed , fibrosis has been observed in diabetic patients with NAFLD even independently of NASH , and genetic variants that impair insulin receptor ( InsR ) signaling favor fibrosis development in NAFLD patients .
10-1	1346-1352	Indeed	_	_	_	_
10-2	1353-1354	,	_	_	_	_
10-3	1355-1363	fibrosis	abstract	giv	coref	10-29
10-4	1364-1367	has	_	_	_	_
10-5	1368-1372	been	_	_	_	_
10-6	1373-1381	observed	_	_	_	_
10-7	1382-1384	in	_	_	_	_
10-8	1385-1393	diabetic	person[84]	new[84]	coref	10-32[95_84]
10-9	1394-1402	patients	person[84]	new[84]	_	_
10-10	1403-1407	with	person[84]	new[84]	_	_
10-11	1408-1413	NAFLD	person[84]|abstract	new[84]|giv	coref	10-32
10-12	1414-1418	even	_	_	_	_
10-13	1419-1432	independently	_	_	_	_
10-14	1433-1435	of	_	_	_	_
10-15	1436-1440	NASH	substance|abstract[87]	giv|giv[87]	coref|coref	19-11|19-11
10-16	1441-1442	,	abstract[87]	giv[87]	_	_
10-17	1443-1446	and	abstract[87]	giv[87]	_	_
10-18	1447-1454	genetic	abstract[87]|object[88]	giv[87]|giv[88]	_	_
10-19	1455-1463	variants	abstract[87]|object[88]	giv[87]|giv[88]	_	_
10-20	1464-1468	that	_	_	_	_
10-21	1469-1475	impair	_	_	_	_
10-22	1476-1483	insulin	object|substance[90]	giv|new[90]	coref|coref	18-11|18-11
10-23	1484-1492	receptor	substance[90]	new[90]	_	_
10-24	1493-1494	(	_	_	_	_
10-25	1495-1499	InsR	object	new	coref	19-30
10-26	1500-1501	)	_	_	_	_
10-27	1502-1511	signaling	_	_	_	_
10-28	1512-1517	favor	_	_	_	_
10-29	1518-1526	fibrosis	abstract|abstract[93]	giv|giv[93]	coref|coref	11-6|11-6
10-30	1527-1538	development	abstract[93]	giv[93]	_	_
10-31	1539-1541	in	abstract[93]	giv[93]	_	_
10-32	1542-1547	NAFLD	abstract[93]|abstract|person[95]	giv[93]|giv|giv[95]	coref|coref|coref|coref	12-5|19-17[180_95]|12-5|19-17[180_95]
10-33	1548-1556	patients	abstract[93]|person[95]	giv[93]|giv[95]	_	_
10-34	1557-1558	.	_	_	_	_

#Text=The mechanism whereby IR aggravates fibrosis may be related to reduced extracellular matrix ( ECM ) degradation and to the induction of proteins involved in collagen crosslinking .
11-1	1559-1562	The	abstract[96]	new[96]	_	_
11-2	1563-1572	mechanism	abstract[96]	new[96]	_	_
11-3	1573-1580	whereby	_	_	_	_
11-4	1581-1583	IR	abstract	giv	coref	16-24
11-5	1584-1594	aggravates	_	_	_	_
11-6	1595-1603	fibrosis	abstract	giv	coref	14-22
11-7	1604-1607	may	_	_	_	_
11-8	1608-1610	be	_	_	_	_
11-9	1611-1618	related	_	_	_	_
11-10	1619-1621	to	_	_	_	_
11-11	1622-1629	reduced	abstract[99]	new[99]	appos	11-15[0_99]
11-12	1630-1643	extracellular	abstract[99]	new[99]	_	_
11-13	1644-1650	matrix	abstract[99]	new[99]	_	_
11-14	1651-1652	(	_	_	_	_
11-15	1653-1656	ECM	abstract	giv	_	_
11-16	1657-1658	)	_	_	_	_
11-17	1659-1670	degradation	abstract	new	_	_
11-18	1671-1674	and	_	_	_	_
11-19	1675-1677	to	_	_	_	_
11-20	1678-1681	the	abstract[102]	new[102]	_	_
11-21	1682-1691	induction	abstract[102]	new[102]	_	_
11-22	1692-1694	of	abstract[102]	new[102]	_	_
11-23	1695-1703	proteins	abstract[102]|substance	new[102]|giv	_	_
11-24	1704-1712	involved	_	_	_	_
11-25	1713-1715	in	_	_	_	_
11-26	1716-1724	collagen	organization|abstract[105]	new|new[105]	_	_
11-27	1725-1737	crosslinking	abstract[105]	new[105]	_	_
11-28	1738-1739	.	_	_	_	_

#Text=A new perspective of NAFLD pathogenesis and management is provided by epigenetics , which modulate transcriptome in response to environmental cues .
12-1	1740-1741	A	abstract[106]	new[106]	_	_
12-2	1742-1745	new	abstract[106]	new[106]	_	_
12-3	1746-1757	perspective	abstract[106]	new[106]	_	_
12-4	1758-1760	of	abstract[106]	new[106]	_	_
12-5	1761-1766	NAFLD	abstract[106]|abstract|abstract[108]	new[106]|giv|giv[108]	coref|coref	14-19|14-19
12-6	1767-1779	pathogenesis	abstract[106]|abstract[108]	new[106]|giv[108]	_	_
12-7	1780-1783	and	abstract[106]	new[106]	_	_
12-8	1784-1794	management	abstract[106]|person	new[106]|new	_	_
12-9	1795-1797	is	_	_	_	_
12-10	1798-1806	provided	_	_	_	_
12-11	1807-1809	by	_	_	_	_
12-12	1810-1821	epigenetics	abstract	new	coref	16-11
12-13	1822-1823	,	_	_	_	_
12-14	1824-1829	which	_	_	_	_
12-15	1830-1838	modulate	_	_	_	_
12-16	1839-1852	transcriptome	abstract	new	_	_
12-17	1853-1855	in	_	_	_	_
12-18	1856-1864	response	abstract[112]	new[112]	coref	14-6[132_112]
12-19	1865-1867	to	abstract[112]	new[112]	_	_
12-20	1868-1881	environmental	abstract[112]|abstract[113]	new[112]|new[113]	_	_
12-21	1882-1886	cues	abstract[112]|abstract[113]	new[112]|new[113]	_	_
12-22	1887-1888	.	_	_	_	_

#Text=In particular , microRNAs ( miRNAs ) are short non-protein coding , single-strand RNAs of 19 – 22 nucleotides that regulate gene expression and cell-to-cell communication as it occurs between hepatocytes and hepatic stellate cells ( HSCs ) during fibrogenesis .
13-1	1889-1891	In	_	_	_	_
13-2	1892-1902	particular	_	_	_	_
13-3	1903-1904	,	_	_	_	_
13-4	1905-1914	microRNAs	abstract	new	appos	13-6
13-5	1915-1916	(	_	_	_	_
13-6	1917-1923	miRNAs	abstract	giv	coref	13-9[116_0]
13-7	1924-1925	)	_	_	_	_
13-8	1926-1929	are	_	_	_	_
13-9	1930-1935	short	abstract[116]	giv[116]	coref	17-9[0_116]
13-10	1936-1947	non-protein	abstract[116]	giv[116]	_	_
13-11	1948-1954	coding	abstract[116]	giv[116]	_	_
13-12	1955-1956	,	abstract[116]	giv[116]	_	_
13-13	1957-1970	single-strand	abstract[116]|abstract[117]	giv[116]|new[117]	_	_
13-14	1971-1975	RNAs	abstract[116]|abstract[117]	giv[116]|new[117]	_	_
13-15	1976-1978	of	abstract[116]|abstract[117]	giv[116]|new[117]	_	_
13-16	1979-1981	19	abstract[116]|abstract[117]|quantity	giv[116]|new[117]|new	_	_
13-17	1982-1983	–	abstract[116]|abstract[117]	giv[116]|new[117]	_	_
13-18	1984-1986	22	abstract[116]|abstract[117]|place[119]	giv[116]|new[117]|new[119]	_	_
13-19	1987-1998	nucleotides	abstract[116]|abstract[117]|place[119]	giv[116]|new[117]|new[119]	_	_
13-20	1999-2003	that	_	_	_	_
13-21	2004-2012	regulate	_	_	_	_
13-22	2013-2017	gene	abstract|abstract[121]	new|new[121]	coref|coref	14-3[131_121]|14-3[131_121]
13-23	2018-2028	expression	abstract[121]	new[121]	_	_
13-24	2029-2032	and	_	_	_	_
13-25	2033-2045	cell-to-cell	abstract[122]	new[122]	ana	13-28[0_122]
13-26	2046-2059	communication	abstract[122]	new[122]	_	_
13-27	2060-2062	as	_	_	_	_
13-28	2063-2065	it	abstract	giv	_	_
13-29	2066-2072	occurs	_	_	_	_
13-30	2073-2080	between	_	_	_	_
13-31	2081-2092	hepatocytes	person	new	_	_
13-32	2093-2096	and	_	_	_	_
13-33	2097-2104	hepatic	substance|place[126]	giv|new[126]	coref|coref|coref|coref	19-40|21-12[205_126]|19-40|21-12[205_126]
13-34	2105-2113	stellate	place[126]	new[126]	_	_
13-35	2114-2119	cells	place[126]	new[126]	_	_
13-36	2120-2121	(	_	_	_	_
13-37	2122-2126	HSCs	place	new	coref	17-15
13-38	2127-2128	)	_	_	_	_
13-39	2129-2135	during	_	_	_	_
13-40	2136-2148	fibrogenesis	abstract	new	coref	23-24
13-41	2149-2150	.	_	_	_	_

#Text=Alteration of miRNA expression in response to genetic/epigenetic factors or environmental conditions may contribute to steatosis onset and NAFLD progression to fibrosis and cancer , mirroring the histological features and the molecular events occurring in NAFLD .
14-1	2151-2161	Alteration	abstract[129]	new[129]	_	_
14-2	2162-2164	of	abstract[129]	new[129]	_	_
14-3	2165-2170	miRNA	abstract[129]|person|abstract[131]	new[129]|new|giv[131]	coref|coref	19-19[182_131]|19-19[182_131]
14-4	2171-2181	expression	abstract[129]|abstract[131]	new[129]|giv[131]	_	_
14-5	2182-2184	in	abstract[129]|abstract[131]	new[129]|giv[131]	_	_
14-6	2185-2193	response	abstract[129]|abstract[131]|abstract[132]	new[129]|giv[131]|giv[132]	_	_
14-7	2194-2196	to	abstract[129]|abstract[131]|abstract[132]	new[129]|giv[131]|giv[132]	_	_
14-8	2197-2215	genetic/epigenetic	abstract[129]|abstract[131]|abstract[132]|abstract[133]	new[129]|giv[131]|giv[132]|giv[133]	coref	16-13[157_133]
14-9	2216-2223	factors	abstract[129]|abstract[131]|abstract[132]|abstract[133]	new[129]|giv[131]|giv[132]|giv[133]	_	_
14-10	2224-2226	or	abstract[129]|abstract[131]|abstract[132]|abstract[133]	new[129]|giv[131]|giv[132]|giv[133]	_	_
14-11	2227-2240	environmental	abstract[129]|abstract[131]|abstract[132]|abstract[133]|abstract[134]	new[129]|giv[131]|giv[132]|giv[133]|new[134]	_	_
14-12	2241-2251	conditions	abstract[129]|abstract[131]|abstract[132]|abstract[133]|abstract[134]	new[129]|giv[131]|giv[132]|giv[133]|new[134]	_	_
14-13	2252-2255	may	_	_	_	_
14-14	2256-2266	contribute	_	_	_	_
14-15	2267-2269	to	_	_	_	_
14-16	2270-2279	steatosis	abstract|event[136]	giv|new[136]	_	_
14-17	2280-2285	onset	event[136]	new[136]	_	_
14-18	2286-2289	and	_	_	_	_
14-19	2290-2295	NAFLD	abstract|event[138]	giv|giv[138]	coref|coref|coref|coref	14-36|15-33[153_138]|14-36|15-33[153_138]
14-20	2296-2307	progression	event[138]	giv[138]	_	_
14-21	2308-2310	to	event[138]	giv[138]	_	_
14-22	2311-2319	fibrosis	event[138]|abstract	giv[138]|giv	coref	17-22[169_0]
14-23	2320-2323	and	event[138]	giv[138]	_	_
14-24	2324-2330	cancer	event[138]|event	giv[138]|new	coref	23-27
14-25	2331-2332	,	_	_	_	_
14-26	2333-2342	mirroring	_	_	_	_
14-27	2343-2346	the	abstract[141]|abstract[142]	new[141]|new[142]	ana|ana	15-3[0_142]|15-3[0_142]
14-28	2347-2359	histological	abstract[141]|abstract[142]	new[141]|new[142]	_	_
14-29	2360-2368	features	abstract[141]|abstract[142]	new[141]|new[142]	_	_
14-30	2369-2372	and	abstract[142]	new[142]	_	_
14-31	2373-2376	the	abstract[142]|event[143]	new[142]|giv[143]	_	_
14-32	2377-2386	molecular	abstract[142]|event[143]	new[142]|giv[143]	_	_
14-33	2387-2393	events	abstract[142]|event[143]	new[142]|giv[143]	_	_
14-34	2394-2403	occurring	_	_	_	_
14-35	2404-2406	in	_	_	_	_
14-36	2407-2412	NAFLD	organization	giv	coref	16-18[158_0]
14-37	2413-2414	.	_	_	_	_

#Text=Thus , they could be exploited as attractive candidate biomarkers for an accurate profiling of the different stages of liver injury , enabling early and non-invasive diagnosis and the clinical monitoring of the disease progression .
15-1	2415-2419	Thus	_	_	_	_
15-2	2420-2421	,	_	_	_	_
15-3	2422-2426	they	abstract	giv	_	_
15-4	2427-2432	could	_	_	_	_
15-5	2433-2435	be	_	_	_	_
15-6	2436-2445	exploited	_	_	_	_
15-7	2446-2448	as	_	_	_	_
15-8	2449-2459	attractive	_	_	_	_
15-9	2460-2469	candidate	_	_	_	_
15-10	2470-2480	biomarkers	_	_	_	_
15-11	2481-2484	for	_	_	_	_
15-12	2485-2487	an	abstract[146]	new[146]	_	_
15-13	2488-2496	accurate	abstract[146]	new[146]	_	_
15-14	2497-2506	profiling	abstract[146]	new[146]	_	_
15-15	2507-2509	of	abstract[146]	new[146]	_	_
15-16	2510-2513	the	abstract[146]|abstract[147]	new[146]|new[147]	_	_
15-17	2514-2523	different	abstract[146]|abstract[147]	new[146]|new[147]	_	_
15-18	2524-2530	stages	abstract[146]|abstract[147]	new[146]|new[147]	_	_
15-19	2531-2533	of	abstract[146]|abstract[147]	new[146]|new[147]	_	_
15-20	2534-2539	liver	abstract[146]|abstract[147]|object|event[149]	new[146]|new[147]|giv|new[149]	coref|coref	17-22|17-22
15-21	2540-2546	injury	abstract[146]|abstract[147]|event[149]	new[146]|new[147]|new[149]	_	_
15-22	2547-2548	,	_	_	_	_
15-23	2549-2557	enabling	_	_	_	_
15-24	2558-2563	early	abstract[150]	new[150]	_	_
15-25	2564-2567	and	abstract[150]	new[150]	_	_
15-26	2568-2580	non-invasive	abstract[150]	new[150]	_	_
15-27	2581-2590	diagnosis	abstract[150]	new[150]	_	_
15-28	2591-2594	and	_	_	_	_
15-29	2595-2598	the	abstract[151]	new[151]	_	_
15-30	2599-2607	clinical	abstract[151]	new[151]	_	_
15-31	2608-2618	monitoring	abstract[151]	new[151]	_	_
15-32	2619-2621	of	abstract[151]	new[151]	_	_
15-33	2622-2625	the	abstract[151]|event[153]	new[151]|giv[153]	_	_
15-34	2626-2633	disease	abstract[151]|abstract|event[153]	new[151]|giv|giv[153]	coref	22-36[223_0]
15-35	2634-2645	progression	abstract[151]|event[153]	new[151]|giv[153]	_	_
15-36	2646-2647	.	_	_	_	_

#Text=Therefore , we aimed to explore the mechanisms through which epigenetics and environmental factors interact to promote progressive NAFLD in the context of IR .
16-1	2648-2657	Therefore	_	_	_	_
16-2	2658-2659	,	_	_	_	_
16-3	2660-2662	we	person	acc	ana	17-5
16-4	2663-2668	aimed	_	_	_	_
16-5	2669-2671	to	_	_	_	_
16-6	2672-2679	explore	_	_	_	_
16-7	2680-2683	the	abstract[155]	new[155]	_	_
16-8	2684-2694	mechanisms	abstract[155]	new[155]	_	_
16-9	2695-2702	through	_	_	_	_
16-10	2703-2708	which	_	_	_	_
16-11	2709-2720	epigenetics	abstract	giv	_	_
16-12	2721-2724	and	_	_	_	_
16-13	2725-2738	environmental	abstract[157]	giv[157]	_	_
16-14	2739-2746	factors	abstract[157]	giv[157]	_	_
16-15	2747-2755	interact	_	_	_	_
16-16	2756-2758	to	_	_	_	_
16-17	2759-2766	promote	_	_	_	_
16-18	2767-2778	progressive	organization[158]	giv[158]	coref	19-49[0_158]
16-19	2779-2784	NAFLD	organization[158]	giv[158]	_	_
16-20	2785-2787	in	_	_	_	_
16-21	2788-2791	the	abstract[159]	new[159]	_	_
16-22	2792-2799	context	abstract[159]	new[159]	_	_
16-23	2800-2802	of	abstract[159]	new[159]	_	_
16-24	2803-2805	IR	abstract[159]|abstract	new[159]|giv	coref	17-13[164_0]
16-25	2806-2807	.	_	_	_	_

#Text=To this purpose , we first assessed which miRNAs were deregulated by IR in HSCs whose activation represents the hallmark of liver fibrosis .
17-1	2808-2810	To	_	_	_	_
17-2	2811-2815	this	abstract[161]	new[161]	_	_
17-3	2816-2823	purpose	abstract[161]	new[161]	_	_
17-4	2824-2825	,	_	_	_	_
17-5	2826-2828	we	person	giv	ana	18-3
17-6	2829-2834	first	_	_	_	_
17-7	2835-2843	assessed	_	_	_	_
17-8	2844-2849	which	_	_	_	_
17-9	2850-2856	miRNAs	abstract	giv	coref	18-6[171_0]
17-10	2857-2861	were	_	_	_	_
17-11	2862-2873	deregulated	_	_	_	_
17-12	2874-2876	by	_	_	_	_
17-13	2877-2879	IR	abstract[164]	giv[164]	coref	19-9[0_164]
17-14	2880-2882	in	abstract[164]	giv[164]	_	_
17-15	2883-2887	HSCs	abstract[164]|place	giv[164]|giv	coref	18-12[173_0]
17-16	2888-2893	whose	abstract[166]	new[166]	_	_
17-17	2894-2904	activation	abstract[166]	new[166]	_	_
17-18	2905-2915	represents	_	_	_	_
17-19	2916-2919	the	abstract[167]	new[167]	_	_
17-20	2920-2928	hallmark	abstract[167]	new[167]	_	_
17-21	2929-2931	of	abstract[167]	new[167]	_	_
17-22	2932-2937	liver	abstract[167]|object|abstract[169]	new[167]|giv|giv[169]	coref|coref|coref|coref	18-17[174_169]|22-36|18-17[174_169]|22-36
17-23	2938-2946	fibrosis	abstract[167]|abstract[169]	new[167]|giv[169]	_	_
17-24	2947-2948	.	_	_	_	_

#Text=Secondly , we evaluated whether the miRNAs differentially expressed in insulin resistant HSCs could impact on NAFLD-related fibrosis by using an experimental model of IR-NASH .
18-1	2949-2957	Secondly	_	_	_	_
18-2	2958-2959	,	_	_	_	_
18-3	2960-2962	we	person	giv	ana	20-8
18-4	2963-2972	evaluated	_	_	_	_
18-5	2973-2980	whether	_	_	_	_
18-6	2981-2984	the	abstract[171]	giv[171]	coref	19-19[0_171]
18-7	2985-2991	miRNAs	abstract[171]	giv[171]	_	_
18-8	2992-3006	differentially	_	_	_	_
18-9	3007-3016	expressed	_	_	_	_
18-10	3017-3019	in	_	_	_	_
18-11	3020-3027	insulin	abstract	giv	coref	19-40[190_0]
18-12	3028-3037	resistant	place[173]	giv[173]	coref	21-21[0_173]
18-13	3038-3042	HSCs	place[173]	giv[173]	_	_
18-14	3043-3048	could	_	_	_	_
18-15	3049-3055	impact	_	_	_	_
18-16	3056-3058	on	_	_	_	_
18-17	3059-3072	NAFLD-related	abstract[174]	giv[174]	_	_
18-18	3073-3081	fibrosis	abstract[174]	giv[174]	_	_
18-19	3082-3084	by	_	_	_	_
18-20	3085-3090	using	_	_	_	_
18-21	3091-3093	an	abstract[175]	new[175]	_	_
18-22	3094-3106	experimental	abstract[175]	new[175]	_	_
18-23	3107-3112	model	abstract[175]	new[175]	_	_
18-24	3113-3115	of	abstract[175]	new[175]	_	_
18-25	3116-3123	IR-NASH	abstract[175]|abstract	new[175]|new	_	_
18-26	3124-3125	.	_	_	_	_

#Text=Thus , to investigate the independent contribution of IR and NASH that is usually intertwined in patients on miRNAs expression , IR was induced in mice by haploinsufficiency for InsR ( InsR+/− ) , which determines an impairment of hepatic insulin signaling recapitulating that has been observed in NAFLD patients .
19-1	3126-3130	Thus	_	_	_	_
19-2	3131-3132	,	_	_	_	_
19-3	3133-3135	to	_	_	_	_
19-4	3136-3147	investigate	_	_	_	_
19-5	3148-3151	the	abstract[177]	new[177]	_	_
19-6	3152-3163	independent	abstract[177]	new[177]	_	_
19-7	3164-3176	contribution	abstract[177]	new[177]	_	_
19-8	3177-3179	of	abstract[177]	new[177]	_	_
19-9	3180-3182	IR	abstract[177]|abstract	new[177]|giv	coref	19-22
19-10	3183-3186	and	abstract[177]	new[177]	_	_
19-11	3187-3191	NASH	abstract[177]|abstract	new[177]|giv	coref	20-5[193_0]
19-12	3192-3196	that	_	_	_	_
19-13	3197-3199	is	_	_	_	_
19-14	3200-3207	usually	_	_	_	_
19-15	3208-3219	intertwined	_	_	_	_
19-16	3220-3222	in	_	_	_	_
19-17	3223-3231	patients	person[180]	giv[180]	coref	19-49[192_180]
19-18	3232-3234	on	person[180]	giv[180]	_	_
19-19	3235-3241	miRNAs	person[180]|person|abstract[182]	giv[180]|giv|giv[182]	coref|coref|coref|coref	21-5[202_182]|21-8[203_0]|21-5[202_182]|21-8[203_0]
19-20	3242-3252	expression	person[180]|abstract[182]	giv[180]|giv[182]	_	_
19-21	3253-3254	,	_	_	_	_
19-22	3255-3257	IR	abstract	giv	coref	20-25
19-23	3258-3261	was	_	_	_	_
19-24	3262-3269	induced	_	_	_	_
19-25	3270-3272	in	_	_	_	_
19-26	3273-3277	mice	animal	new	coref	22-25[219_0]
19-27	3278-3280	by	_	_	_	_
19-28	3281-3299	haploinsufficiency	abstract[185]	new[185]	_	_
19-29	3300-3303	for	abstract[185]	new[185]	_	_
19-30	3304-3308	InsR	abstract[185]|abstract	new[185]|giv	appos	19-32
19-31	3309-3310	(	_	_	_	_
19-32	3311-3318	InsR+/−	abstract	giv	coref	22-10[214_0]
19-33	3319-3320	)	_	_	_	_
19-34	3321-3322	,	_	_	_	_
19-35	3323-3328	which	_	_	_	_
19-36	3329-3339	determines	_	_	_	_
19-37	3340-3342	an	abstract[188]	new[188]	_	_
19-38	3343-3353	impairment	abstract[188]	new[188]	_	_
19-39	3354-3356	of	abstract[188]	new[188]	_	_
19-40	3357-3364	hepatic	abstract[188]|abstract|abstract[190]	new[188]|giv|giv[190]	coref|coref	22-24[0_190]|22-24[0_190]
19-41	3365-3372	insulin	abstract[188]|abstract[190]	new[188]|giv[190]	_	_
19-42	3373-3382	signaling	_	_	_	_
19-43	3383-3397	recapitulating	_	_	_	_
19-44	3398-3402	that	_	_	_	_
19-45	3403-3406	has	_	_	_	_
19-46	3407-3411	been	_	_	_	_
19-47	3412-3420	observed	_	_	_	_
19-48	3421-3423	in	_	_	_	_
19-49	3424-3429	NAFLD	abstract|person[192]	giv|giv[192]	coref|coref	23-36|23-36
19-50	3430-3438	patients	person[192]	giv[192]	_	_
19-51	3439-3440	.	_	_	_	_

#Text=Conversely , to model fibrogenic NASH , we exploited the methionine choline deficient ( MCD ) diet , which impairs phospholipid metabolism without altering IR .
20-1	3441-3451	Conversely	_	_	_	_
20-2	3452-3453	,	_	_	_	_
20-3	3454-3456	to	_	_	_	_
20-4	3457-3462	model	_	_	_	_
20-5	3463-3473	fibrogenic	abstract[193]	giv[193]	_	_
20-6	3474-3478	NASH	abstract[193]	giv[193]	_	_
20-7	3479-3480	,	_	_	_	_
20-8	3481-3483	we	person	giv	ana	21-3
20-9	3484-3493	exploited	_	_	_	_
20-10	3494-3497	the	abstract[196]	new[196]	_	_
20-11	3498-3508	methionine	substance|abstract[196]	new|new[196]	_	_
20-12	3509-3516	choline	abstract[196]	new[196]	_	_
20-13	3517-3526	deficient	_	_	_	_
20-14	3527-3528	(	abstract[198]	new[198]	_	_
20-15	3529-3532	MCD	substance|abstract[198]	new|new[198]	_	_
20-16	3533-3534	)	abstract[198]	new[198]	_	_
20-17	3535-3539	diet	abstract[198]	new[198]	_	_
20-18	3540-3541	,	_	_	_	_
20-19	3542-3547	which	_	_	_	_
20-20	3548-3555	impairs	_	_	_	_
20-21	3556-3568	phospholipid	abstract[199]	new[199]	coref	23-18[231_199]
20-22	3569-3579	metabolism	abstract[199]	new[199]	_	_
20-23	3580-3587	without	_	_	_	_
20-24	3588-3596	altering	_	_	_	_
20-25	3597-3599	IR	abstract	giv	coref	23-38
20-26	3600-3601	.	_	_	_	_

#Text=Finally , we tested the expression of the candidate miRNAs in immortalized human hepatoma cells ( HepG2 ) and in HSCs ( LX-2 ) in the presence or absence of miRNA mimics .
21-1	3602-3609	Finally	_	_	_	_
21-2	3610-3611	,	_	_	_	_
21-3	3612-3614	we	person	giv	ana	22-3
21-4	3615-3621	tested	_	_	_	_
21-5	3622-3625	the	abstract[202]	giv[202]	coref	22-15[216_202]
21-6	3626-3636	expression	abstract[202]	giv[202]	_	_
21-7	3637-3639	of	abstract[202]	giv[202]	_	_
21-8	3640-3643	the	abstract[202]|abstract[203]	giv[202]|giv[203]	_	_
21-9	3644-3653	candidate	abstract[202]|abstract[203]	giv[202]|giv[203]	_	_
21-10	3654-3660	miRNAs	abstract[202]|abstract[203]	giv[202]|giv[203]	_	_
21-11	3661-3663	in	abstract[202]|abstract[203]	giv[202]|giv[203]	_	_
21-12	3664-3676	immortalized	abstract[202]|abstract[203]|place[205]	giv[202]|giv[203]|giv[205]	_	_
21-13	3677-3682	human	abstract[202]|abstract[203]|place[205]	giv[202]|giv[203]|giv[205]	_	_
21-14	3683-3691	hepatoma	abstract[202]|abstract[203]|abstract|place[205]	giv[202]|giv[203]|new|giv[205]	_	_
21-15	3692-3697	cells	abstract[202]|abstract[203]|place[205]	giv[202]|giv[203]|giv[205]	_	_
21-16	3698-3699	(	_	_	_	_
21-17	3700-3705	HepG2	abstract	new	coref	24-6
21-18	3706-3707	)	_	_	_	_
21-19	3708-3711	and	_	_	_	_
21-20	3712-3714	in	_	_	_	_
21-21	3715-3719	HSCs	abstract	giv	appos	21-23
21-22	3720-3721	(	_	_	_	_
21-23	3722-3726	LX-2	abstract	giv	coref	24-8
21-24	3727-3728	)	_	_	_	_
21-25	3729-3731	in	_	_	_	_
21-26	3732-3735	the	abstract[209]	giv[209]	_	_
21-27	3736-3744	presence	abstract[209]	giv[209]	_	_
21-28	3745-3747	or	_	_	_	_
21-29	3748-3755	absence	abstract[210]	new[210]	_	_
21-30	3756-3758	of	abstract[210]	new[210]	_	_
21-31	3759-3764	miRNA	abstract[210]|abstract	new[210]|new	_	_
21-32	3765-3771	mimics	_	_	_	_
21-33	3772-3773	.	_	_	_	_

#Text=Here , we showed that miR-101-3p was downregulated in InsR+/− HSCs and hepatocytes , its expression was reduced even in total livers of insulin resistant mice , and it was associated with all stages of liver disease .
22-1	3774-3778	Here	_	_	_	_
22-2	3779-3780	,	_	_	_	_
22-3	3781-3783	we	person	giv	_	_
22-4	3784-3790	showed	_	_	_	_
22-5	3791-3795	that	_	_	_	_
22-6	3796-3806	miR-101-3p	object	new	coref	23-11
22-7	3807-3810	was	_	_	_	_
22-8	3811-3824	downregulated	_	_	_	_
22-9	3825-3827	in	_	_	_	_
22-10	3828-3835	InsR+/−	abstract[214]	giv[214]	ana	22-15[0_214]
22-11	3836-3840	HSCs	abstract[214]	giv[214]	_	_
22-12	3841-3844	and	abstract[214]	giv[214]	_	_
22-13	3845-3856	hepatocytes	abstract[214]	giv[214]	_	_
22-14	3857-3858	,	_	_	_	_
22-15	3859-3862	its	abstract|abstract[216]	giv|giv[216]	ana|ana	22-29|22-29
22-16	3863-3873	expression	abstract[216]	giv[216]	_	_
22-17	3874-3877	was	_	_	_	_
22-18	3878-3885	reduced	_	_	_	_
22-19	3886-3890	even	_	_	_	_
22-20	3891-3893	in	_	_	_	_
22-21	3894-3899	total	object[217]	new[217]	_	_
22-22	3900-3906	livers	object[217]	new[217]	_	_
22-23	3907-3909	of	object[217]	new[217]	_	_
22-24	3910-3917	insulin	object[217]|abstract	new[217]|giv	coref	23-15
22-25	3918-3927	resistant	object[217]|animal[219]	new[217]|giv[219]	_	_
22-26	3928-3932	mice	object[217]|animal[219]	new[217]|giv[219]	_	_
22-27	3933-3934	,	_	_	_	_
22-28	3935-3938	and	_	_	_	_
22-29	3939-3941	it	abstract	giv	_	_
22-30	3942-3945	was	_	_	_	_
22-31	3946-3956	associated	_	_	_	_
22-32	3957-3961	with	_	_	_	_
22-33	3962-3965	all	abstract[221]	new[221]	_	_
22-34	3966-3972	stages	abstract[221]	new[221]	_	_
22-35	3973-3975	of	abstract[221]	new[221]	_	_
22-36	3976-3981	liver	abstract[221]|object|abstract[223]	new[221]|giv|giv[223]	_	_
22-37	3982-3989	disease	abstract[221]|abstract[223]	new[221]|giv[223]	_	_
22-38	3990-3991	.	_	_	_	_

#Text=Consistently with these results , target prediction analysis revealed that miR-101-3p is involved in insulin signaling , lipid metabolism , cell proliferation , fibrogenesis , and cancer susceptibility , possibly representing a molecular signature in NAFLD during IR .
23-1	3992-4004	Consistently	_	_	_	_
23-2	4005-4009	with	_	_	_	_
23-3	4010-4015	these	abstract[224]	new[224]	_	_
23-4	4016-4023	results	abstract[224]	new[224]	_	_
23-5	4024-4025	,	_	_	_	_
23-6	4026-4032	target	_	_	_	_
23-7	4033-4043	prediction	event|abstract[226]	new|new[226]	_	_
23-8	4044-4052	analysis	abstract[226]	new[226]	_	_
23-9	4053-4061	revealed	_	_	_	_
23-10	4062-4066	that	_	_	_	_
23-11	4067-4077	miR-101-3p	object	giv	_	_
23-12	4078-4080	is	_	_	_	_
23-13	4081-4089	involved	_	_	_	_
23-14	4090-4092	in	_	_	_	_
23-15	4093-4100	insulin	abstract|abstract[229]	giv|new[229]	_	_
23-16	4101-4110	signaling	abstract[229]	new[229]	_	_
23-17	4111-4112	,	_	_	_	_
23-18	4113-4118	lipid	object|abstract[231]	giv|giv[231]	_	_
23-19	4119-4129	metabolism	abstract[231]	giv[231]	_	_
23-20	4130-4131	,	_	_	_	_
23-21	4132-4136	cell	place|event[233]	new|new[233]	coref|coref	24-10[0_233]|24-10[0_233]
23-22	4137-4150	proliferation	event[233]	new[233]	_	_
23-23	4151-4152	,	_	_	_	_
23-24	4153-4165	fibrogenesis	abstract	giv	_	_
23-25	4166-4167	,	_	_	_	_
23-26	4168-4171	and	_	_	_	_
23-27	4172-4178	cancer	abstract|abstract[236]	giv|new[236]	_	_
23-28	4179-4193	susceptibility	abstract[236]	new[236]	_	_
23-29	4194-4195	,	_	_	_	_
23-30	4196-4204	possibly	_	_	_	_
23-31	4205-4217	representing	_	_	_	_
23-32	4218-4219	a	abstract[237]	new[237]	_	_
23-33	4220-4229	molecular	abstract[237]	new[237]	_	_
23-34	4230-4239	signature	abstract[237]	new[237]	_	_
23-35	4240-4242	in	abstract[237]	new[237]	_	_
23-36	4243-4248	NAFLD	abstract[237]|organization	new[237]|giv	_	_
23-37	4249-4255	during	_	_	_	_
23-38	4256-4258	IR	event	giv	_	_
23-39	4259-4260	.	_	_	_	_

#Text=Furthermore , miR-101-3p overexpression in HepG2 and LX-2 reduced proliferation , migration , and invasiveness , regulating pro-fibrotic and pro-carcinogenic markers .
24-1	4261-4272	Furthermore	_	_	_	_
24-2	4273-4274	,	_	_	_	_
24-3	4275-4285	miR-101-3p	abstract[240]	new[240]	_	_
24-4	4286-4300	overexpression	abstract[240]	new[240]	_	_
24-5	4301-4303	in	abstract[240]	new[240]	_	_
24-6	4304-4309	HepG2	abstract[240]|abstract	new[240]|giv	_	_
24-7	4310-4313	and	abstract[240]	new[240]	_	_
24-8	4314-4318	LX-2	abstract[240]|abstract	new[240]|giv	_	_
24-9	4319-4326	reduced	_	_	_	_
24-10	4327-4340	proliferation	event	giv	_	_
24-11	4341-4342	,	_	_	_	_
24-12	4343-4352	migration	abstract	new	_	_
24-13	4353-4354	,	_	_	_	_
24-14	4355-4358	and	_	_	_	_
24-15	4359-4371	invasiveness	abstract	new	_	_
24-16	4372-4373	,	_	_	_	_
24-17	4374-4384	regulating	_	_	_	_
24-18	4385-4397	pro-fibrotic	abstract[246]	new[246]	_	_
24-19	4398-4401	and	abstract[246]	new[246]	_	_
24-20	4402-4418	pro-carcinogenic	abstract[246]	new[246]	_	_
24-21	4419-4426	markers	abstract[246]	new[246]	_	_
24-22	4427-4428	.	_	_	_	_
